Medtronic Releases Details On New Renal Denervation Trials
This article was originally published in The Gray Sheet
Executive Summary
FDA has granted an investigational device exemption for the SPYRAL HTN renal denervation global clinical trial program, designed to avoid the problems that led Medtronic's prior pivotal study to miss its endpoint.
You may also be interested in...
Cardiovascular Catch-Up: ACC Brings Encouraging Renal Denervation And TAVR Data For Medtronic
Medtech Insight’s Cardiovascular Catch-Up highlights recent news and insights from cardiovascular device companies – big and small – from the last few weeks. This edition focuses on news from the recent American College of Cardiology Scientific Sessions.
Medtronic Hopes To Refine Renal Denervation Hypertension Therapy With New Trial
The 50-patient SPYRAL DYSTAL trial will evaluate the benefits of a new targeted renal denervation approach with the Symplicity Spyral renal denervation system in patients with uncontrolled hypertension.
California Bill To Age-Restrict Sales Of Diet Pills Further Along Than Other States’ Legislation
CA, MA and NJ legislatures remain in session with bills active proposing regulations similar to NY law effective 22 April requiring retailers, including online, to ask for proof of age when customers buying consumer health products containing ingredients labeled or promoted for weight loss and bodybuilding benefits appear younger than 18.